Sorrento Therapeutics, Inc. Sustainability Profile
Sorrento Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on the development of innovative therapies for cancer and autoimmune diseases. Founded in 2006, Sorrento has made significant strides in the biotechnology sector, particularly in the fields of immunotherapy and antibody development. The company is renowned for its proprietary antibody platform, which includes unique products such as the COVID-19 therapeutic candidate, COVI-MSC, and various cancer treatment modalities. Sorrento's commitment to advancing healthcare solutions has positioned it as a notable player in the biopharmaceutical industry, with a robust pipeline aimed at addressing unmet medical needs. With operations extending across major regions, Sorrento Therapeutics continues to drive innovation and improve patient outcomes globally.
DitchCarbon Score
How does Sorrento Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sorrento Therapeutics, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sorrento Therapeutics, Inc.'s reported carbon emissions
Sorrento Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data for the latest year. As such, there are no specific figures available for their Scope 1, Scope 2, or Scope 3 emissions. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, nor are there any climate pledges noted. Given the absence of emissions data and reduction initiatives, Sorrento Therapeutics appears to be in the early stages of addressing its carbon footprint and climate impact. The lack of reported emissions and targets may reflect a broader trend within the biotechnology sector, where companies are increasingly recognising the importance of sustainability but may not yet have fully developed their climate strategies.
How Carbon Intensive is Sorrento Therapeutics, Inc.'s Industry?
How Carbon Intensive is Sorrento Therapeutics, Inc.'s Location?
Sorrento Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sorrento Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.